載入中
NYSEHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$18.73
+US$0.21 · +1.13%
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
前收盤價
US$18.73
+US$0.21 · +1.13%
盤中時間採用ET。市場資料可能有所延遲。
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
日內區間
目前US$18.73
52週區間
目前US$18.73
盤中時間採用ET。市場資料可能有所延遲。
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig. To further its innovative endeavors, Takeda engages in a wide array of strategic partnerships. These include out-licensing arrangements, notably with Neurocrine Biosciences, Inc.; numerous collaboration and in-licensing agreements with institutions like the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., Ovid Therapeutics Inc., and Evox Therapeutics Ltd.; and a licensing deal with ProThera Biologics Inc. The company also fosters research collaborations and licensing agreements with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio. Furthermore, it maintains strategic alliances with Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc., Carmine Therapeutics, KSQ Therapeutics, and Anima Biotech. Founded in 1781, Takeda Pharmaceutical Company Limited is headquartered in Tokyo, Japan.
日內區間
目前US$18.73
52週區間
目前US$18.73
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（JPY） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4.78兆 JPY | 4.58兆 JPY | 4.26兆 JPY | 4.03兆 JPY | 3.57兆 JPY |
| 銷貨成本 | 2.34兆 JPY | 1.58兆 JPY | 1.43兆 JPY | 1.24兆 JPY | 1.11兆 JPY |
| 毛利 | 2.44兆 JPY | 3兆 JPY | 2.83兆 JPY | 2.78兆 JPY | 2.46兆 JPY |
| 研究與開發 | 7166.88億 JPY | 7302.27億 JPY | 7299.24億 JPY | 6333.25億 JPY | 5260.87億 JPY |
| 銷售、一般及管理費用 | 1.15兆 JPY | 1.1兆 JPY | 1.05兆 JPY | 9973.09億 JPY | 8863.61億 JPY |
| 營業費用 | 1.87兆 JPY | 2.66兆 JPY | 2.62兆 JPY | 2.29兆 JPY | 2兆 JPY |
| 利息收入 | 2239.13億 JPY | 196.38億 JPY | 7809.7萬 JPY | 55.08億 JPY | 45.91億 JPY |
| 利息支出 | 3791.36億 JPY | 1373.11億 JPY | 10.62億 JPY | 1169.73億 JPY | 1224.32億 JPY |
| 折舊和攤銷 | 7211.27億 JPY | 7613.96億 JPY | 7280.02億 JPY | 6644億 JPY | 5831.51億 JPY |
| 營業利益 | 5730.42億 JPY | 3425.86億 JPY | 2140.75億 JPY | 4905.05億 JPY | 4608.44億 JPY |
| 淨利 | 2033.27億 JPY | 1079.28億 JPY | 1440.67億 JPY | 3170.17億 JPY | 2300.59億 JPY |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
First Trust Value Line Dividend Index FundFVD3189.73萬0.42%76.22億 USD0.62%US$47.66+0.13%
VanEck Pharmaceutical ETFPPH2835.02萬2.77%10.37億 USD0.36%US$110.49+1.20%
Avantis International Equity ETFAVDE1034.24萬0.05%192.24億 USD0.23%US$89.80+0.58%
ActivePassive International Equity ETFAPIE284.19萬0.25%11.41億 USD0.45%US$38.56+0.65%
Vanguard FTSE All-World ex-US ETFVEU221.83萬0.00%986億 USD0.04%US$82.82+0.78%
iShares Dynamic Equity Active ETFBDYN145.78萬0.05%31.59億 USD0.40%US$28.1232+0.69%
Adasina Social Justice All Cap Global ETFJSTC110.04萬0.37%3.01億 USD0.89%US$22.80+0.95%
iShares Flexible Equity Active ETFBFLX105.01萬0.05%21.89億 USD0.40%US$26.1102+0.67%First Trust Value Line Dividend Index FundFVDVanEck Pharmaceutical ETFPPHAvantis International Equity ETFAVDEActivePassive International Equity ETFAPIEVanguard FTSE All-World ex-US ETFVEUiShares Dynamic Equity Active ETFBDYNAdasina Social Justice All Cap Global ETFJSTCiShares Flexible Equity Active ETFBFLXAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
